Dimerix Limited (ASX:DXB) has confirmed it’s begun recruiting adolescent kidney disease patients in Mexico, now that its ‘ACTION3‘ Phase 3 clinical trial location has been selected. Ages range from 12 to 17.
HotCopper users were perusing the announcement pre-market trades – the most popular announcement of the day thus far.
Dimerix is expanding its scope beyond Mexico, too – the company flagged an additional 14 specialist paediatric clinical sites are set to open in Argentina, the UK and the US. It’s also appointed an expert nephrologist to its board.
“I am delighted to be extending my relationship with Dimerix for their FSGS program,” NYU School of Medicine Dr. Howard Trachtman – the expert nephrologist in question – said. For all intents and purposes, nephrology is kidney disease.
“FSGS remains an area of huge unmet need with similarly poor outcomes in both children and adults. There are still no approved therapies to delay or prevent progression to kidney failure.”
As for the Phase 3 ACTION3 trial, the company expects “interim analysis” to come in around halfway through CY2025. The company says it has enough cash on its own to fund the study.
“Patients in this “adolescent or paediatric cohort” of the ACTION3 Phase 3 clinical trial will also be blinded, randomised (i.e. unknowingly placed on either placebo or DMX-200) and will be followed for a period of two years,” DXB wrote on Thursday.
DXB last traded at 39cps.